Burosumab (Crysvita)
Drug timelines are a Plus or Pro feature.
1 regulatory and trial event tracked for Burosumab (Crysvita), covering 2019-05-22 to 2019-05-22. Get the full timeline:
Most recent: Clinical Trial Update: Study of KRN23 (Burosumab), a Recombinant Fully Human Monoclonal Antibody Against Fibroblast Growth Factor 23 (FGF23), in Pediatric Subjects With X-linked Hypophosphatemia (XLH) [Phase 2]